| Cardiovascular Function and Risk Factors | Lifetime | 80 | US 57 | 99.82 |
| Heart Failure Treatment and Management | Lifetime | 45 | US 29 | 99.81 |
| Cardiac pacing and defibrillation studies | Lifetime | 62 | US 33 | 99.74 |
| Health Systems, Economic Evaluations, Quality of Life | Lifetime | 124 | US 60 | 99.55 |
| Medication Adherence and Compliance | Lifetime | 54 | US 40 | 98.76 |
| Cardiac Arrhythmias and Treatments | Lifetime | 300 | US 152 | 99.14 |
| Cardiac Imaging and Diagnostics | Lifetime | 432 | US 229 | 99.28 |
| Pharmaceutical Practices and Patient Outcomes | Lifetime | 186 | US 77 | 98.08 |
| Ultrasound in Clinical Applications | Lifetime | 111 | US 50 | 98.16 |
| Atrial Fibrillation Management and Outcomes | Lifetime | 428 | US 181 | 98.93 |
| Cardiac, Anesthesia and Surgical Outcomes | Lifetime | 987 | US 500 | 98.23 |
| Acute Myocardial Infarction Research | Lifetime | 467 | US 212 | 98.58 |
| Potassium and Related Disorders | Lifetime | 91 | US 54 | 97.95 |
| Blood Pressure and Hypertension Studies | Lifetime | 621 | US 257 | 98.25 |
| Cardiac electrophysiology and arrhythmias | Lifetime | 807 | US 399 | 98.16 |
| Healthcare Policy and Management | Lifetime | 597 | US 415 | 97.27 |
| Lipoproteins and Cardiovascular Health | Lifetime | 706 | US 310 | 97.22 |
| Chemotherapy-induced cardiotoxicity and mitigation | Lifetime | 215 | US 120 | 95.55 |
| Emergency and Acute Care Studies | Lifetime | 771 | US 427 | 96.39 |
| Cardiac Health and Mental Health | Lifetime | 725 | US 349 | 95.68 |
| Primary Care and Health Outcomes | Lifetime | 876 | US 502 | 95.89 |
| Clinical practice guidelines implementation | Lifetime | 631 | US 168 | 94.10 |
| Healthcare cost, quality, practices | Lifetime | 702 | US 393 | 92.63 |
| Pharmaceutical Economics and Policy | Lifetime | 751 | US 324 | 92.62 |
| Cardiovascular Health and Risk Factors | Lifetime | 705 | US 384 | 92.12 |
| Pericarditis and Cardiac Tamponade | Lifetime | 743 | US 330 | 86.05 |
| Heart rate and cardiovascular health | Lifetime | 430 | US 130 | 78.32 |
| Cardiovascular Function and Risk Factors | 2021-2025 | 75 | US 41 | 99.50 |
| Heart Failure Treatment and Management | 2021-2025 | 52 | US 27 | 99.52 |
| Cardiac pacing and defibrillation studies | 2021-2025 | 62 | US 25 | 99.09 |
| Health Systems, Economic Evaluations, Quality of Life | 2021-2025 | 587 | US 197 | 95.13 |
| Potassium and Related Disorders | 2021-2025 | 40 | US 20 | 96.71 |
| Medication Adherence and Compliance | 2021-2025 | 110 | US 44 | 92.03 |
| Lipoproteins and Cardiovascular Health | 2021-2025 | 550 | US 175 | 90.33 |
| Diabetes Treatment and Management | 2021-2025 | 973 | US 308 | 90.45 |
| Pharmaceutical Economics and Policy | 2021-2025 | 303 | US 119 | 85.80 |
| Healthcare Policy and Management | 2021-2025 | 854 | US 596 | 81.94 |
| Primary Care and Health Outcomes | 2021-2025 | 847 | US 440 | 79.37 |
| Patient Satisfaction in Healthcare | 2021-2025 | 994 | US 396 | 68.88 |
| Hyperglycemia and glycemic control in critically ill and hospitalized patients | 2021-2025 | 971 | US 323 | 59.54 |
